RSS-Feed abonnieren
DOI: 10.1055/s-0030-1260806
Total Synthesis and Cytotoxicity Evaluation of an Oxazole Analogue of Tubulysin U
Publikationsverlauf
Publikationsdatum:
21. Juni 2011 (online)

Abstract
Tubulysins are strongly cytotoxic natural tetrapeptides with potent antiproliferative, antimitotic, and antiangiogenic activities which might find use in oncology. We herein report the first total synthesis of a stereoisomerically pure oxazole analogue of tubulysin U, which was found to be more cytotoxic than the thiazole-containing natural product. Additionally, we have developed an improved and scalable synthetic route towards the Tup fragment of the tubulysins.
Key words
tubulysin - oxazole - SAR study - chemotherapy - cytotoxicity
- 1
Sasse F.Steinmetz H.Höfle H.Reichembach H.
J. Antibiot. 2000, 53: 879 - 2
Steinmetz H.Glaser N.Herdtweck E.Sasse F.Reichenbach H.Höfle G. Angew. Chem. Int. Ed. 2004, 43: 4888 ; Angew. Chem. 2004, 116, 4996 - 3 For a recent study on the tubulin-bound
structure of tubulysin A, see:
Kubicek K.Grimm SK.Orts J.Sasse F.Carlomagno T. Angew. Chem. Int. Ed. 2010, 49: 4809 - 4
Jackson JR.Patrick DR.Dar MM.Huang PS. Nat. Rev. Cancer 2007, 7: 107 - 5
Höfle G.Glaser N.Leibold T.Karama U.Sasse F.Steinmetz H. Pure Appl.Chem. 2003, 75: 167 - 6 For a review on drug-conjugated monoclonal
antibodies for the treatment of cancer, see:
Lambert JM. Curr. Opin. Pharmacol. 2005, 5: 543 - 7a
Leamon CP.Reddy JA.Vetzel M.Dorton R.Westrick E.Parker N.Wang Y.Vlahov I. Cancer Res. 2008, 68: 9839Reference Ris Wihthout Link - 7b
Vlahov IR.Wang Y.Kleindl PJ.Leamon CP. Bioorg. Med. Chem. Lett. 2008, 18: 4558Reference Ris Wihthout Link - 7c
Reddy JA.Dorton R.Dawson A.Vetzel M.Parker N.Nicoson JS.Westrick E.Klein PJ.Wang Y.Vlahov IR.Leamon CP. Mol. Pharm. 2009, 6: 1518Reference Ris Wihthout Link - 7d
Kularatne SA.Wang K.Santhapuram H.-KR.Low PS. Mol. Pharm. 2009, 6: 780Reference Ris Wihthout Link - 8a
Höfle G,Leibold T, andSteinmetz H. inventors; DE 10008089.Reference Ris Wihthout Link - See also:
- 8b
Neri D.Fossati G.Zanda M. ChemMedChem 2006, 1: 175Reference Ris Wihthout Link - 9
Sani M.Fossati G.Huguenot F.Zanda M. Angew. Chem. Int. Ed. 2007, 46: 3526 - 10a
Balasubramanian R.Raghavan B.Begaye A.Sackett DL.Fecik RA. J. Med. Chem. 2009, 52: 238Reference Ris Wihthout Link - 10b
Balasubramanian R.Raghavan B.Steele JC.Sackett DL.Fecik RA. Bioorg. Med. Chem. Lett. 2008, 18: 2996Reference Ris Wihthout Link - 10c
Raghavan B.Balasubramanian R.Steele JC.Sackett DL.Fecik RA. J. Med. Chem. 2008, 51: 1530Reference Ris Wihthout Link - 10d
Patterson AW.Peltier HM.Ellman JA. J. Org. Chem. 2008, 73: 4362Reference Ris Wihthout Link - 10e
Patterson AW.Peltier HM.Sasse H.Ellman JA. Chem. Eur. J. 2007, 13: 9534Reference Ris Wihthout Link - 10f
Wipf P.Wang Z. Org. Lett. 2007, 9: 1605Reference Ris Wihthout Link - 10g
Chandrasekhar S.Mahipal B.Kavitha M. J. Org. Chem. 2009, 74: 9531Reference Ris Wihthout Link - 10h
Pando O.Dörner S.Preusentanz R.Denkert A.Porzel A.Richter W.Wessjohann L. Org. Lett. 2009, 11: 5567Reference Ris Wihthout Link - 10i
Ullrich A.Herrmann J.Müller R.Kazmaier U. Eur. J. Org. Chem. 2009, 6367Reference Ris Wihthout Link - 10j
Peltier HM.McMahon JP.Patterson AW.Ellman JA. J. Am. Chem. Soc. 2006, 128: 16018Reference Ris Wihthout Link - 10k
Shibue T.Hirai T.Okamoto I.Morita N.Masu H.Azumaya I.Tamura O. Chem. Eur. J. 2010, 16: 11678Reference Ris Wihthout Link - 10l
Shibue T.Okamoto I.Morita N.Morita H.Hirasawa Y.Hosoya T.Tamura O. Bioorg. Med. Chem. Lett. 2011, 21: 431Reference Ris Wihthout Link - 10m
Wang Z.McPherson PA.Raccor BS.Balachandran R.Zhu G.Day BW.Vogt A.Wipf P. Chem. Biol. Drug Des. 2007, 70: 75Reference Ris Wihthout Link - 11
Wipf P.Takada T.Rishel MJ. Org. Lett. 2004, 6: 4057 - 12
Cheng ZZ.Hamada Y.Shioiri T. Synlett 1997, 109 - 13
Phillips AJ.Uto Y.Wipf P.Reno MJ.Williams DR. Org. Lett. 2000, 2: 1165 - 14
Barrish JC.Singh J.Spergel SH.Han W.-C.Kissick TP.Kronenthal DR.Mueller RH. J. Org. Chem. 1993, 58: 4494 - For other methods accomplishing the mentioned transfor-mation, see:
- 16a
Williams DR.Lowder PD.Gu Y.-G.Brooks DA. Tetrahedron Lett. 1997, 38: 331Reference Ris Wihthout Link - 16b
Chattopadhyay SK.Kempson J.McNeil A.Pattenden G.Reader M.Rippon DE.Waite D. J. Chem. Soc., Perkin Trans. 1 2000, 2415Reference Ris Wihthout Link - 17
Phillips AJ.Uto Y.Wipf P.Reno MJ.Williams DR. Org. Lett. 2000, 2: 1165 - 18
Corey EJ.Helal CJ. Angew. Chem. Int. Ed. 1998, 37: 1986 ; Angew. Chem. 1998, 110, 2092 - 22
Fraser AV.Woster PM.Wallace HM. Biochem. J. 2002, 367: 307 ; and references cited therein
References and Notes
Characterisation
Data for Compound 4b
R
f
= 0.35
(EtOAc-hexane = 3:7). ¹H NMR
(400 MHz, CDCl3): δ = 8.21 (s, 1 H),
4.22 (q, J = 7.1
Hz, 2 H), 2.51 (s, 3 H), 1.19 (t, J = 7.1
Hz, 3 H). ¹³C NMR (100.5 MHz, CDCl3): δ = 185.1,
160.1, 157.6, 146.0, 134.7, 61.5, 26.6, 14.1. ESI-LCMS: m/z = 183.9 [M + H]+,
205.8 [M + Na]+.
Characterisation
Data for Compound 5b
R
f
= 0.43
(EtOAc-hexane = 45:55). FT-IR (film): νmax = 3374.8,
1734.5, 1660.4, 1505.4, 1391.9, 757.4 cm-¹. ¹H NMR
(400 MHz, CDCl3): δ = 8.14 (s, 1 H),
4.84 (d, J = 10.8 Hz,
1 H), 4.72 (br s, 1 H), 4.55 (d, J = 9.3
Hz, 1 H), 4.31 (q, J = 7.1
Hz, 2 H), 3.73-3.63 (m, 1 H), 2.02 (ddd, J = 13.7, 11.3,
2.5 Hz, 1 H), 1.80-1.65 (m, 2 H), 1.38 (s, 9 H), 1.30 (t, J = 7.1 Hz,
3 H), 0.90 (d, J = 6.9
Hz, 3 H), 0.88 (d, J = 6.9 Hz,
3 H). ¹³C NMR (100.5 MHz, CDCl3): δ = 165.6,
161.1, 157.6, 143.9, 133.2, 80.1, 64.6, 61.0, 52.1, 39.1, 32.1,
28.2, 19.2, 18.2, 14.2. ESI-LCMS: m/z = 379.1 [M + Na]+.
Characterisation
Data for Compound 21
R
f
= 0.3
(MeOH-CH2Cl2 = 1:9). [α]D
²³ +8.6
(c 1.0, MeOH). ¹H
NMR (400 MHz, CD3OD): δ = 7.46-7.15
(m, 5 H), 3.63 (s, 3 H), 3.59-3.47 (m, 1 H), 3.04 (dd, J = 19.9,
6.2 Hz, 1 H), 2.91 (dd, J = 13.7,
7.7 Hz, 1 H), 2.79-2.65 (m, 1 H), 2.08-1.95 (m,
1 H), 1.16 (d, J = 6.9
Hz, 3 H). ¹³C NMR (100.5 MHz, CD3OD): δ = 178.1,
137.8, 131.3, 130.9, 129.3, 53.3, 41.1, 37.9, 37.7, 18.7. ESI-LCMS: m/z = 221.9 [M + H]+.
Characterisation
Data for the Tubulysin U Analogue oxa-1
R
f
= 0.53
(MeOH-CHCl3 = 12:88). ¹H
NMR (250 MHz, CD3OD): δ = 8.14 (s,
1 H), 7.19-7.00 (m, 5 H), 5.61 (dd, J = 11.1,
2.4 Hz, 1 H), 4.24-4.22 (m, 1 H), 4.10 (d, J = 8.3 Hz,
1 H), 3.90-3.75 (m, 1 H), 3.13-2.88 (m, 2 H),
2.77 (d, J = 6.6
Hz, 2 H), 2.52-2.36 (m, 2 H), 2.35 (s, 3 H), 2.27-2.09 (m,
1 H), 2.02 (s, 3 H), 1.99-1.10 (m, 13 H), 1.05 (d, J = 6.8 Hz,
3 H), 0.92-0.74 (m, 12 H). ¹³C
NMR (63 MHz, CD3OD): δ = 176.7, 173.7,
173.1, 171.6, 163.4, 162.1, 143.0, 139.7, 137.5, 130.5, 129.3, 127.3,
69.5, 66.9, 59.6, 56.3, 51.8, 50.7, 44.0, 42.0, 39.3, 37.5, 35.7,
33.8, 32.7, 31.0, 25.9, 25.3, 23.5, 20.6, 19.5, 18.6, 16.2, 14.4,
11.1. ESI-LCMS: m/z = 698.2 [M + H]+,
720.2 [M + Na]+.